Your browser doesn't support javascript.
loading
Efficacy of an Anti-Semaphorin 3A Neutralizing Antibody in a Male Experimental Retinal Vein Occlusion Mouse Model.
Nakamura, Shinsuke; Nishinaka, Anri; Hidaka, Yae; Shimazawa, Masamitsu; Thomas, Leo; Bakker, Remko A; Hara, Hideaki.
Afiliação
  • Nakamura S; Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
  • Nishinaka A; Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
  • Hidaka Y; Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
  • Shimazawa M; Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
  • Thomas L; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach and der Riß, Germany.
  • Bakker RA; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach and der Riß, Germany.
  • Hara H; Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.
Invest Ophthalmol Vis Sci ; 63(8): 14, 2022 07 08.
Article em En | MEDLINE | ID: mdl-35822950
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Retinianas / Oclusão da Veia Retiniana / Edema Macular Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Invest Ophthalmol Vis Sci Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Retinianas / Oclusão da Veia Retiniana / Edema Macular Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Invest Ophthalmol Vis Sci Ano de publicação: 2022 Tipo de documento: Article